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Abstract
Background: The prevalence of multimorbidity (the presence of two or more long-term conditions) is rising
internationally. Multimorbidity affects patients by increasing their burden of symptoms, but is also likely to increase
the self-care demands, or treatment burden, that they experience. Treatment burden refers to the effort expended
in operationalising treatments, navigating healthcare systems and managing relations with healthcare providers.
This is an important problem for people with chronic illness such as stroke. Polypharmacy is an important marker of
both multimorbidity and burden of treatment. In this study, we examined the prevalence of multimorbidity and
polypharmacy in a large, nationally representative population of primary care patients with and without stroke,
adjusting for age, sex and deprivation.
Methods: A cross-sectional study of 1,424,378 participants aged 18 years and over, from 314 primary care practices
in Scotland that were known to be demographically representative of the Scottish adult population. Data included
information on the presence of stroke and another 39 long-term conditions, plus prescriptions for regular medications.
Results: In total, 35,690 people (2.5%) had a diagnosis of stroke. Of the 39 comorbidities examined, 35 were
significantly more common in people with stroke. Of the people with a stroke, the proportion that had one or more
additional morbidities present (94.2%) was almost twice that in the control group (48%) (odds ratio (OR) adjusted for
age, sex and socioeconomic deprivation 5.18; 95% confidence interval (CI) 4.95 to 5.43). In the stroke group, 12.6% had
a record of 11 or more repeat prescriptions compared with only 1.5% of the control group (OR adjusted for age, sex,
deprivation and morbidity count 15.84; 95% CI 14.86 to 16.88). Limitations include the use of data collected for clinical
rather than research purposes, a lack of consensus in the literature on the definition of certain long-term conditions,
and the absence of statistical weighting in the measurement of multimorbidity, although the latter was deemed
suitable for descriptive analyses.
Conclusions: Multimorbidity and polypharmacy were strikingly more common in those with a diagnosis of stroke
compared with those without. This has important implications for clinical guidelines and the design of health services.
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Background
Multimorbidity, defined as the presence of two or more
long-term conditions, is becoming a global challenge for
policy-makers, clinicians, and patients [1-3]. Treatment
advances and increasing sub-specialisation of health ser-
vices have improved functional outcomes for those with
long-term conditions, but such changes have resulted in
an increasing burden of treatment demands on patients,
particularly those with multimorbidity [3,4]. Treatment
burden is defined as the workload of healthcare for patients
and the impact of this on their wellbeing [5]. It includes
information gathering, attending multiple appointments,
taking medications, enacting self-care, and, in countries
that lack a health service that is free at the point of care,
organising finances to pay for treatments [5-8]. There is a
risk that patients become overburdened by their treat-
ments, which can mean failure to adhere to management
plans, thus resulting in ineffective treatment and wasted
resources [3,9-11].
One aspect of treatment burden described above is
polypharmacy, which can contribute to other treat-
ment burdens such as adverse drug events [12,13].
Polypharmacy is most commonly defined as the use of
multiple (usually five or ten) prescribed medications
[14-16]. Although there is no strong evidence to sup-
port the use of any particular threshold, the risk of
drug-related problems seems to increase with each
additional medication prescribed [17,18]. There is a known
association between number of morbidities and polyphar-
macy [19-21], with a study using routine Scottish health
records finding that of those with two clinical conditions,
20.8% were receiving four to nine medications, and 1.1%
were receiving ten or more medications; for patients
with six or more comorbidities, these values were 47.7%
and 41.7%, respectively [19]. A systematic literature re-
view investigating the relationship between the number
of chronic conditions and healthcare utilisation outcomes
found that about 60% of elderly respondents with zero or
one condition reported taking prescription medications.
This percentage went up to more than 90% for those with
two or three conditions, and approached 100% for those
with more than five conditions [20], supporting the
premise that those with higher numbers of conditions
to manage are more likely to experience higher levels
of treatment burden [3]. Other aspects of treatment
burden such as healthcare utilisation have also been
shown to be associated with multimorbidity [20,22].
Stroke is a condition that can have a considerable
impact on an individual’s life. A recent systematic re-
view of the qualitative literature revealed that people
who have had a stroke experience four main areas of
treatment burden: making sense of stroke management
and planning care, interacting with others, enacting
management strategies, and reflecting on management
[23]. Poor communication between patients and pro-
fessionals was a common experience, exacerbated by
fragmentation of health services and poor communication
between healthcare providers themselves, aspects of stroke
care likely to be exacerbated by multimorbidity [24-26].
Surprisingly, there has been limited exploration of multi-
morbidity or polypharmacy in people with stroke, the field
being characterised by small-scale studies and a small num-
ber of conditions under examination [19,27-36]. Those
studies that have examined stroke in relation to other long-
term conditions have suggested that stroke is one of the
diseases most significantly associated with polypharmacy
[19,33], but there is a lack of large-scale studies examining
a broad range of medications and comorbidities.
In the current study, using a large, nationally representa-
tive cross-sectional primary care dataset, we examined the
prevalence of multimorbidity and polypharmacy in people
with and without stroke.
Methods
Study design and participants
This was a cross-sectional study based on a nationally
representative dataset managed by the Primary Care
Clinical Informatics Unit at the University of Aberdeen
in Scotland. This fully anonymised dataset contains
clinical data on all people that were alive and permanently
registered with 314 primary care practices in Scotland on
31 March 2007. Comprising approximately one-third of
the Scottish adult population, this sample has been shown
to be representative of this population [37]. In the UK,
registration with a medical practice is required for an indi-
vidual to access National Health Service (NHS) healthcare
in the community. It is estimated that over 98% of the
population are registered with a medical practice [38],
which systematically records information on each patient
in an electronic medical record, for the purposes of regis-
tration and subsequent everyday medical care. We exam-
ined data extracted from medical records and collated for
a previous study of multimorbidity that had examined
the presence of forty conditions [1]. The NHS National
Research Ethics Service approved the use of these data
for research purposes. Patient consent was not deemed
necessary due to full anonymisation of the data.
Data collected and disease definition
The data examined consisted of the following variables:
sex, age, socioeconomic deprivation (measured from
patients’ postcodes using the Carstairs score [39]), counts
of regularly prescribed medications and the presence of 40
long-term conditions, including stroke.
There is no ‘gold standard’ method for the measure-
ment of multimorbidity, therefore the forty long-term
conditions included had been chosen and defined based
on a recent systematic review [40] and expert consensus
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[1]. Existing definitions for each long-term condition
were used if possible, mainly those used in the Quality
and Outcomes Framework (QOF) or by NHS Scotland
[1,41,42]. If no standard definition was available, or there
was concern about under-recording, then conditions
were defined by the clinical members of the research
team. For example, depression was defined as the pres-
ence of a QOF Read Code in the past year or receipt of
four or more prescriptions for antidepressant drugs
(excluding low-dose tricyclics, which are usually used
for chronic pain) in the past year [1]. The definitions of
all morbidities examined are given in supplementary
material (see Additional file 1). Comorbidity was mea-
sured using a count of long-term conditions [43], with
morbidities being noted as either mental health or
physical morbidities. The original analysis measured
the presence of a combined group of stroke or transient is-
chaemic attack (TIA), but for the purposes of this analysis,
the presence of stroke alone was defined using the QOF
Business Rules code set [41], and TIA was ignored.
As there are no standard definitions of regularly
prescribed treatments or measure of polypharmacy,
we utilised a count of current regular prescriptions,
including tablets, inhalers, stoma care and topical therapies
[17,18]. Regular (‘repeat’) prescriptions are clearly dis-
tinguished in UK general practice electronic medical
records from one-off (‘acute’) prescriptions such as
those for most antibiotics. For the purposes of this
analysis, any regular prescription that was still active
(that is, available for issue on request) on the date of
extraction and that had been prescribed in the past
84 days was counted as current. This time frame was
selected as this was the maximum length of a repeat
prescription in Scotland at the time of data collection.
Statistical analysis
Analyses were predicated on a comparison of the character-
istics of people with stroke (cases) and those without stroke
(controls). First, the numbers of morbidities and prescribed
medications in stroke cases and controls were calculated,
and proportions within each group computed. Second,
logistic regression, which produces ORs, was used to
summarise the relationship between stroke and the
presence of comorbidities and prescribed medications.
ORs were initially unadjusted – for the purposes of
comparison – then adjusted for the key confounding
factors of age, sex and socioeconomic deprivation. Age
and deprivation were used as continuous variables.
Deprivation was measured using the Carstairs score,
which is widely used in health research. The Carstairs
score is based on four census indicators: low social
class, lack of car ownership, overcrowding and male
unemployment. The scores have been described as a
measure that reflects access to ‘those goods and services,
resources and amenities and of a physical environment
which are customary in society’ [39]. The scores therefore
cannot be described as a measure of the extent of an
individual’s material wellbeing, but are rather a sum-
mary measure applied to populations contained within
small geographic localities. Further adjustment for number
of morbidities was made when polypharmacy was the
characteristic of interest. Associations between numbers
of morbidities and prescriptions were assessed using
Spearman correlation coefficients. For the purposes of this
analysis, a P < 0.05 was deemed statistically significant. All
analyses were carried out using IBM Statistical Package
for the Social Sciences (SPSS) Statistics software (V21).
Results
The analyses were based on 1,424,378 individuals (724,949
women) aged 18 years and over who were registered with
a general practitioner. In total, 35,690 people (2.5%) had a
diagnosis of stroke. As anticipated, the mean age of people
in the stroke group (72.68 ± 12.21) was higher than that of
the controls 47.36 ± 17.93). For the demographic character-
istics for each group, see Additional file 2.
Comorbidities
Table 1 shows the number and percent of total morbid-
ities, physical morbidities and mental health morbidities
in the stroke and control groups, along with ORs for
stroke in relation to these variables. Multimorbidity was
common in stroke: of the study members with stroke,
the percentage that had one or more additional morbid-
ities present (94.2%) was almost twice that in the control
group (48%) (OR adjusted for age, sex and deprivation
5.18; 95% CI 4.95 to 5.43). Disaggregating the data
into type of morbidity revealed that physical morbidity
was markedly more common in people with stroke
(adjusted OR 4.50; 95% CI 4.31 to 4.68), and mental
health morbidity was also more common but the relation-
ship was less strong (adjusted OR 2.10; 95% CI 2.05 to 2.15).
In terms of assessing whether these differences exist across
different age groups, a sub-analysis for age groups 35–44
years and 75+ years was performed (see Additional file 3).
This indicated that differences were larger for the younger
age group, and increased with the number of conditions
(a similar picture was found for number of repeat pre-
scriptions). However, the skewed distribution of stroke
prevalence towards the oldest age groups make any
assessment of differences by age problematic, owing to
the small sample sizes in the youngest age groups.
The ten most frequent comorbidities present in people
with a diagnosis of stroke were: hypertension (60.9%),
coronary heart disease (29.5%), painful condition (21.9%),
depression (20.7%), diabetes (18.8%), chronic kidney disease
(14.3%), constipation (13.8%), atrial fibrillation (13.0%), thy-
roid disorders (11.9 %), and chronic obstructive pulmonary
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disease (11.9%). Prevalences of all morbidities are shown
in supplementary material (see Additional files 4 and 5).
Figure 1 displays the ORs (adjusted for age, sex and
deprivation) for stroke in relation to the thrity one phys-
ical morbidities examined. The supplementary material
(see Additional file 4) elaborates on this by showing both
the unadjusted and adjusted ORs along with the crude
prevalence of all physical morbidities in the stroke and
control groups. In all, twenty eight of the thirty one
physical morbidities examined were significantly more
common in the stroke group, this was twenty seven after
adjustment for potential confounding factors. For instance,
epilepsy (adjusted OR 4.43; 95% CI 4.14 to 4.74), hyperten-
sion (adjusted OR 2.67; 95% CI 2.61 to 2.73), peripheral
vascular disease (adjusted OR 2.47; 95% CI 2.37 to 2.58),
AF (adjusted OR 2.44; 95% CI 2.36 to 2.53) and CHD
(adjusted OR 2.06; 95% CI 2.01 to 2.11) were all more
common in people experiencing a cerebrovascular dis-
ease event. By contrast, dyspepsia was markedly less
common in the stroke group (adjusted OR 0.63; 95% CI
0.60 to 0.66). Figure 2 shows the ORs (adjusted for age,
sex and deprivation) for stroke in relation to eight mental
health morbidities. The unadjusted and adjusted ORs, along
with the crude prevalence of all mental health morbidities
in the stroke and stroke-free groups, are shown in supple-
mentary material (see Additional file 5). In all, six of the
eight mental health morbidities examined were significantly
more common in the stroke group, and following adjust-
ments, all eight mental health morbidities were significantly
more common. These included drug and medication
use problems (adjusted OR 2.34; 95% CI 2.25 to 2.43),
depression (adjusted OR 2.09; 95% CI 2.03 to 2.15), alcohol
problems (adjusted OR 2.05; 95% CI 1.96 to 2.15) and anx-
iety and stress (adjusted OR 1.61; 95% CI 1.55 to 1.66).
Regular prescriptions
As anticipated, the number of regular prescriptions was
significantly correlated with number of morbidities in
the stroke (Spearman’s ρ = 0.58 P < 0.001) and control
(Spearman’s ρ = 0.75 P < 0.001) groups. Table 2 shows
the number of repeat prescriptions in the stroke and
control groups, and the ORs. Those with stroke were more
likely than the controls to be on a repeat prescription
(adjusted OR 4.53; 95% CI 4.33 to 4.74). In the stroke
group, 12.6% had eleven or more repeat prescriptions
compared with only 1.5% of the control group (OR adjusted
for age, sex, deprivation and morbidity count 15.84; 95% CI
14.86 to 16.88).
Discussion
Summary of findings and implications
Analyses of a large, nationally representative sample of
people in Scotland, a country with universal healthcare,
showed that multimorbidity and polypharmacy were
more common in people with a diagnosis of stroke.
These findings are consistent with our knowledge that
those with stroke are an elderly population with con-
siderable cardiovascular disease risk [44], for whom ef-
fective treatments are increasingly available to alleviate
symptoms and address underlying causal factors [45].
Diagnoses of most chronic conditions were more com-
mon in the stroke group, and this remained the case
Table 1 Stroke status and number of morbidities (N = 1,424,378)
Stroke N (%) No stroke (%) Unadjusted OR
(95% CI)a
Age, gender and
deprivation adjusted
OR (95% CI)a
35690 (100) 1388688 (100)
Total number of morbiditiesb
None 2053 (5.8) 721430 (52.0) 1 1
One-three 17750 (49.7) 551295 (39.7) 11.31 (10.81 to 11.85) 4.35 (4.15 to 4.56)
Four-six 12300 (34.5) 100500 (7.2) 43.01 (41.03 to 45.09) 8.59 (8.17 to 9.04)
Seven or more 3587 (10.1) 15463 (1.1) 81.52 (77.04 to 86.26) 12.81 (12.05 to 13.61)
Number of physical morbiditiesb
None 2769 (7.8) 800202 (57.6) 1 1
One-three 20716 (58.0) 510846 (36.8) 11.72 (11.26 to 12.20) 4.03 (3.86 to 4.20)
Four-six 10414 (29.2) 70709 (5.1) 42.56 (40.79 to 44.41) 7.32 (6.99 to 7.67)
Seven or more 1791 (5.0) 6931 (0.5) 74.68 (70.05 to 79.61) 10.33 (9.64 to 11.05)
Number of mental morbidities
None 21961 (61.5) 1163095 (83.8) 1 1
One-three 13533 (37.9) 223739 (16.1) 3.20 (3.13 to 3.27) 2.08 (2.04 to 2.13)
Four or more 196 (0.5) 1854 (0.1) 5.60 (4.83 to 6.49) 3.56 (3.03 to 4.20)
aall p < 0.001.
bexcluding stroke.
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after adjustment for age, sex and deprivation. In our
preliminary analyses (see Additional file 2), both age
and deprivation were associated with stroke in the ex-
pected directions. This gives us confidence in the novel
results presented herein.
Polypharmacy represents only one aspect of treatment
burden, but is directly measurable, and may be a proxy
measure of wider aspects of burden [17,18]. Multimorbid-
ity is likely to increase treatment burden in several ways.
First, as this study and others have shown, the number of
medications increases with number of conditions [20,21].
Second, treatments may interact, leading to side effects
[5,7,46] and this has the potential to further increase the
volume of work; for example, as new treatments are given
to compensate for interactions [47]. Third, multimorbidity
is likely to increase healthcare contacts and affect the cap-
acity of the individual to follow therapeutic regimens [48];
for example, those with stroke and comorbid arthritis may
find physiotherapy sessions more challenging [49,50].
Fourth, multimorbid patients who become overburdened,
for example by complex medication regimens, may be
less likely to adhere to therapies, leading to poor disease
control and a further escalation of treatments by health
professionals, further increasing treatment burden [3,9,51].
While many pharmacological therapies may be benefi-
cial for those with stroke, a key question is whether
people with stroke have made informed decisions re-
garding whether or not to take so many medications,
given their modest benefits. Although perceived treatment
burden and capacity to cope with any given treatment
burden will vary, we would recommend that patients with
stroke are made aware of the relative benefits of their
drugs, and are empowered to make their own decision
whether to take them.
Figure 1 Odds ratios (with 95% Cl) for physical morbidities in relation to stroke status (adjusted for age, sex, and deprivation).
The stroke group comprised 35,690 people, and the stroke-free group comprised 1,388,688 people.
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Acknowledging and addressing treatment burden in
stroke, particularly for those with multimorbidity, may
improve the patient experience, adherence to therap-
ies, and health outcomes [48]. Minimising unnecessary
treatments, improving co-coordination of services and
making care more patient-centred [23] are likely to
lessen treatment burden, but will necessitate changes
from policy level down to the individual consultation
[3,48,52,53]. Most stroke management guidelines fail
to mention multimorbidity, or merely acknowledge the
more common comorbidities briefly with a lack of practical
advice for clinicians [45,54-57]. We found only one stroke
guideline that acknowledged the issue of polypharmacy,
and again, detailed practical help was lacking [56]. This
issue has been gaining prominence [58,59]. Guidelines
should be redesigned to take account of comorbidity and
treatment burden; for example, by providing guidance on
potential interactions from drug combinations commonly
prescribed for those with stroke and multimorbidity and
how to deal with the possible side effects or interactions
that may arise [47]. In the current study, 21.9% of people
with stroke had a painful condition, 20.7% had depression
and 13.0% had atrial fibrillation, increasing the risk of being
prescribed non-steroidal anti-infammatory drugs (NSAIDs),
Table 2 Stroke status and number of repeat medications (N = 1,424,378)
Stroke N (%) No stroke N (%) Unadjusted OR
(95% CI) a
Age, gender and
deprivation adjusted
OR (95% CI)a
Age, gender, deprivation
and morbidity count
adjusted OR (95% CI)a
35690 (100) 1388688 (100)
Number of medications
None 2447 (6.9%) 863688 (62.2%) 1 1 1
One-two 3038 (8.5%) 240721 (17.3%) 4.45 (4.22 to 4.70) 2.38 (2.26 to 2.52) 2.29 (2.17 to 2.42)
Three-four 6566 (18.4%) 122518 (8.8%) 18.92 (18.05 to 19.82) 6.25 (5.95 to 6.57) 5.78 (5.49 to 6.08)
Five-six 8185 (22.9%) 75512 (5.4%) 38.26 (36.55 to 40.05) 10.50 (9.99 to 11.03) 9.36 (8.89 to 9.86)
Seven-eight 6721 (18.8%) 43344 (3.1%) 54.73 (52.20 to 57.38) 13.90 (13.20 to 14.63) 11.94 (11.29 to 12.62)
Nine-ten 4219 (11.8%) 22536 (1.6%) 66.08 (62.76 to 69.57) 16.22 (15.34 to17.15) 13.44 (12.65 to 14.29)
Eleven or more 4514(12.6%) 20369 (1.5%) 78.22 (74.32 to 82.32) 20.13 (19.05 to 21.27) 15.84 (14.86 to 16.88)
aall p < 0.001.
Figure 2 Odds ratios (with 95% Cl) for mental health morbidities in relation to stroke status (adjusted for age, sex, and deprivation).
The stroke group comprised 35,690 people, and the stroke-free group comprised 1,388,688 people. Note: Drug related problems is any Read code
which records psychoactive substance abuse which includes both drug misuse and prescription drug problems of multiple sources.
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anti-depressants, anti-platelet therapies and anti-coagulants
concomitantly, which increases risk of adverse events, such
as bleeding. Care pathways should be structured around
the patient themselves, rather than the individual condi-
tions, using a more generalist approach that considers
issues such as multimorbidity as well as the individual’s
support network and financial resources [9,60,61].
Strengths and limitations
This analysis was undertaken using data from a large,
nationally representative, primary care sample, and as far
as we are aware, this is the first study on such a scale to
examine multimorbidity and polypharmacy in stroke. This
sample is representative of the Scottish population [37];
however, it may not reflect experience in other countries
and healthcare systems. The prevalence of stroke in this
sample was similar to that shown in other studies [44,62],
further validating the data; however, the data were collected
for clinical rather than research purposes. No standard
methods for measuring multimorbidity or polypharmacy
exist, therefore a pragmatic approach was taken. We
examined thirty nine long-term conditions, which is
substantially more than in previous studies. The rationale
for including the conditions examined and the rules for
identifying the presence of each were described in detail by
the team who previously collated the data [1]. In addition,
any medications bought over the counter or given from
secondary care were not included. However, at the time of
the analysis, prescriptions to people over sixty five years of
age and to many people with chronic conditions were all
free, with others being able to cap their out-of-pocket costs,
thus suggesting a financial incentive to obtain medication
via the primary care practice.
As this is a cross-sectional study, the data we have
were taken from one particular point in time, and there-
fore no conclusions about temporality or causation can
be made. The measure of comorbidity was unweighted,
as the aim was to be descriptive rather than to assess
outcomes. This was deemed to be the most appropriate
method, and is similar to that used by others investigating
the prevalence of multimorbidity [1], but could be viewed
as a limitation, especially as there may be a qualitative
difference between the effects on perceived treatment
burden of long-term conditions that produce regular
symptoms (for example, heart failure) and those that
are asymptomatic (for example, hypertension). We
have no information about stroke severity, which is
also a potential limitation. It should also be noted that
due to the nature of the study, multiple analyses were
carried out. Thus, the large numbers of cases and con-
trols assessed in this study may have identified some
associations that were statistically significant but not
necessarily clinically significant; for example, for con-
ditions such as cancer, glaucoma and asthma, which
had ORs between 1.08 and 1.10 but were statistically
significant with P < 0.001.
Lastly, to explore treatment burden in stroke, this study
examined multimorbidity and polypharmacy, however
there are many more aspects of treatment burden still to
be examined, such as clinic visits, continuity, coordination
of care, and financial burden of therapies. The develop-
ment of a patient-reported measure would enable a more
detailed examination of treatment burden in stroke from
the patient perspective.
Conclusion
In this study, we found that multimorbidity and polyphar-
macy were strikingly more common in those with stroke
than those without. Polypharmacy can be thought of as a
direct measure of one aspect of treatment burden, and we
would suggest that people with stroke should be made
aware of the relative benefits of their drugs so they can
make informed decisions about therapeutic regimens. Both
polypharmacy and multimorbidity are likely to be proxy
markers for other aspects of treatment burden, as patients
face the demands of managing multiple medications and
conditions simultaneously. Clinical guidelines for stroke
need to place greater emphasis on the management of mul-
timorbidity, and further investigation of treatment burden
in stroke is required to inform redesign of health services
to improve patient outcomes.
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